ストックスクリーナーアプリを入手
0.3365
1.97%
0.0065
前日終値:
$0.33
開ける：
$0.3285
24時間の取引高:
377.46K
Relative Volume:
0.28
時価総額：
$20.92M
収益：
-
当期純損益:
$-22.83M
株価収益率:
-0.4259
EPS:
-0.79
ネットキャッシュフロー:
$-20.87M
1週間 パフォーマンス:
+4.76%
1か月 パフォーマンス:
-9.64%
6か月 パフォーマンス:
-23.52%
1年 パフォーマンス:
-83.98%
1日の値動き範囲:
$0.3285
$0.339
1週間の範囲:
$0.31
$0.339
52週間の値動き範囲:
$0.28
$2.95
Cognition Therapeutics Inc Stock (CGTX) Company Profile
名前
Cognition Therapeutics Inc
セクター
電話
412-481-2210
住所
2403 SIDNEY STREET, PITTSBURGH
CGTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
0.3375 | 20.27M | 0 | -22.83M | -20.87M | -0.79 |
|
ONC
Beigene Ltd Adr
|
236.22 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.21 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.285 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.00 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.34 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-19 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | 開始されました | B. Riley Securities | Buy |
| 2021-11-03 | 開始されました | Oppenheimer | Outperform |
Cognition Therapeutics Inc (CGTX) 最新ニュース
Chardan Capital Issues Pessimistic Forecast for Cognition Therapeutics (NASDAQ:CGTX) Stock Price - Defense World
Cognition Therapeutics Presents Preclinical Data On Zervimesine, Stock Down - Nasdaq
Cognition announces outcomes from trial of zervimesine for geographic atrophy - Yahoo Finance
Cognition Therapeutics Inc (NASDAQ: CGTX) Stock Price Forecast: $100 - Stocksregister
Cognition Therapeutics Reports Promising Preclinical Data for Zervimesine in Protecting RPE Cells from Dry AMD at ARVO 2025 - Nasdaq
Cognition Therapeutics Presented Data at Association for - GlobeNewswire
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health - Stock Titan
zervimesine shows promise in dry AMD trial - Investing.com
Cognition Therapeutics Reports Q1 2025 Financials and Progress - TipRanks
Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics - Ophthalmology Times
zervimesine shows promise in dry AMD trial By Investing.com - Investing.com South Africa
Oral Zervimesine Reduces Geographic Atrophy Lesion Growth in Phase 2 Trial - HCPLive
Cognition Therapeutics Announces Positive Phase 2 Trial Results - TipRanks
Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - Santé log
Ratio Examination: Cognition Therapeutics Inc (CGTX)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Cognition Therapeutics Reports Topline Results Showing Oral - GlobeNewswire
Cognition Therapeutics, Inc. (CGTX) Reports Topline Results Showing Oral CT1812 Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - StreetInsider
Cognition Therapeutics, Inc. Reports Topline Results Showing Oral Zervimesine Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - marketscreener.com
Cognition Therapeutics (CGTX) Stock Target Lowered by Chardan Ca - GuruFocus
COGNITION THERAPEUTICS INC SEC 10-Q Report - TradingView
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update - The Manila Times
Cognition Therapeutics, Inc. Advances Alzheimer’s and DLB Programs with FDA Meeting Request and Upcoming Presentations at AAIC and ARVO - Nasdaq
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides ... - Bluefield Daily Telegraph
Caregiver Distress The Hidden Burden Of Dementia With Lewy Bodies — And Why Measuring It Matters - Clinical Leader
Geode Capital Management LLC Raises Holdings in Cognition Therapeutics, Inc. (NASDAQ:CGTX) - Defense World
CES ENERGY SOLUTIONS CORP. ANNOUNCES AMENDMENT AND EXTENSION TO ITS INCREASED CREDIT FACILITY - The Globe and Mail
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Buy” from Analysts - Defense World
Cognition Therapeutics Inc [CGTX] Shares Fall Approximately -76.27% Over the Year - knoxdaily.com
Cognition Therapeutics Inc (CGTX) Stock: Navigating a Year of Volatility - investchronicle.com
CGTX Stock Sees Surge of Approximately 16.59% in Last Five Days - knoxdaily.com
Dry AMD Therapeutics Market Size in 7MM is expected to grow at - openPR.com
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2024 Earnings Call Transcript - MSN
Tscan Therapeutics Inc (TCRX) deserves deeper analysis - uspostnews.com
2025 Is Shaping Up To Be A Big Year For This Drug Maker Working To Cure Dementia - Benzinga
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of “Buy” by Analysts - Defense World
Cognition Therapeutics reports promising Alzheimer’s study results By Investing.com - Investing.com South Africa
Cognition Therapeutics reports promising Alzheimer’s study results - Investing.com
Cognition Therapeutics Presents Results at AD/PD 2025 - GlobeNewswire
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes - TradingView
Breakthrough: Cognition's Alzheimer's Drug Reduces Multiple Disease Markers in Phase 2 Trial - Stock Titan
Equities Analysts Set Expectations for CGTX FY2025 Earnings - Defense World
Contrasting Alpha Cognition (NASDAQ:ACOG) & Cognition Therapeutics (NASDAQ:CGTX) - Defense World
HC Wainwright Has Bearish Estimate for CGTX Q1 Earnings - Defense World
Dementia Associated With Alzheimer’s Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
What is HC Wainwright’s Forecast for CGTX Q1 Earnings? - Defense World
Cognition Therapeutics to Report Biomarker Results from - GlobeNewswire
Cognition Therapeutics to present Alzheimer’s study results By Investing.com - Investing.com South Africa
Agitation in Alzheimer's Disease Market: Analysis - openPR.com
Cognition to Reveal Biomarker Findings Next Week - Baystreet.ca
Cognition Therapeutics to present Alzheimer’s study results - Investing.com India
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025 - The Manila Times
Cognition Therapeutics Inc (CGTX) 財務データ
収益
当期純利益
現金流量
EPS
0.78%
1.61%
大文字化:
|
ボリューム (24 時間):